Agoracom Blog Home

Posts Tagged ‘small cap’

Arizona Voters Approve #Marijuana Legalization Ballot Measure SPONSOR: Hollister Biosciences $HOLL.ca $HSTRF $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 2:15 PM on Wednesday, November 4th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated Cannabis company with products in 280 California dispensaries, over 80 dispensaries throughout Arizona, joint ventures, licensing agreements and partnerships with Global brands. For the period beginning July 1 st , 2020 and ending September 30 th , 2020, Hollister generated record quarterly revenue of CDN$ 12.5 million and CDN$ 1.265 million in EBITDA. Learn More.

Arizona Voters Approve Marijuana Legalization Ballot Measure

  • A measure to legalize marijuana has been approved by Arizona voters, according to a projection by the Associated Press.
  • Advocates have paid close attention to the ballot initiative, as the state’s voters rejected a prior legal cannabis proposal in 2016.
  • Under the new legalization law, adults will be able to possess up to an ounce of marijuana at a time and cultivate up to six plants for personal use.

By Kyle Jaeger

AZ Proposition 207: Legalize Marijuana

CandidateVotesPercent
Yes done1,596,54859.85%
No1,071,25540.15%

2,667,803 votes counted. 81.64% – 98.11% in.

Results tracker sponsored by ETFMG | MJ.

“Until now, Arizona had imposed some of the strictest prohibition laws in the country; in some instances, the possession of even small amounts of marijuana was classified as a felony,” NORML Executive Director Erik Altieri said. “By rejecting this failed policy, no Arizonan going forward will be saddled with a criminal conviction for engaging in the personal possession or cultivation of cannabis, or face the lifelong stigma that comes with it.”

“Proposition 207 will disrupt the illicit market, end low-level marijuana arrests, create jobs and new revenue,” he added. “This result once again shows that marijuana legalization is not exclusively a ‘blue’ state issue, but an issue that is supported by a majority of all Americans—regardless of party politics.”

Polling was mixed heading into Election Day, with surveys consistently showing the proposal ahead, though by differing margins. In September, the Smart and Safe Arizona campaign shared an internal poll with Marijuana Moment that showed 57 percent of likely voters supported the  initiative, but a separate survey found just 46 percent in favor of the policy change. Additional polls last month showed the cannabis measure with a significant and growing lead.

The measure also contains several restorative justice provisions such as allowing individuals with prior marijuana convictions to petition the courts for expungements and establishing a social equity ownership program.

Cannabis sales will be taxed at 16 percent. Tax revenue will cover implementation costs and then be divided among funds for community colleges, infrastructure, a justice reinvestment and public services such as police and firefighters.

The Department of Health Services will be responsible for regulating the program and issuing cannabis business licenses. It will also be tasked with deciding on whether to expand the program to allow for delivery services.

The law technically goes into effect upon passage and after the voters are certified, which is expected to take place on November 30. After that point adults could legally use, possess and cultivate cannabis. However, regulators will still have to promulgate rules for overseeing the commercial industry. They can issue licenses starting in January 2021, and the first shops could be approved by February 1.

“Just four years after legalization was narrowly defeated, voters in Arizona turned out to send a clear message that they support marijuana legalization,” Steve Hawkins, executive director of the Marijuana Policy Project, said. “Following this victory, adults will no longer be treated as criminals for using a substance that is safer than alcohol and will be able to access it from safe and regulated businesses.”

Like other drug policy reform campaigns throughout the U.S., Smart and Safe Arizona faced significant obstacles qualifying its measure for the ballot amid the coronavirus pandemic.

At one point, activists asked the state Supreme Court to allow them to collect signatures electronically amid social distancing mandates, but that request was rejected.

Ultimately, the campaign submitted about 420,000 raw signatures. Secretary of State Katie Hobbs said that her office verified the petitions and determined that approximately 255,080 valid signatures were turned in. At least 237,645 were needed to qualify.

Opponents of the proposal, including Gov. Doug Ducey (R), released official voter guide arguments against the initiative in August. Supporters filed arguments as well, and all were circulated to voters in a pamphlet printed by the state.

Prohibitionists also released a series of attack ads that including misleading claims about what the measure would do and what has occurred in states that have already enacted cannabis legalization.

Source: https://www.marijuanamoment.net/arizona-voters-approve-marijuana-legalization-ballot-measure/

Else Nutrition $BABY.ca $BABYF to Present at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 7:26 AM on Monday, November 2nd, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Announced that it will be participating at this year’s NASPGHAN (North American Society for Pediatric Gastroenterology, Hepatology and Nutrition), November 1 st to 7 th
  • Else’s virtual booth will enable live conversations with small groups, and one-on-one educational sessions, among the nearly 2,600 anticipated attendees
  • The forum will place Else Nutrition alongside some of the leading blue-chip nutrition companies, including Pfizer, Abbott Laboratories, Nestle and Danone

VANCOUVER, BC , Nov. 2, 2020  – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (” Else ” or the ” Company “), a developer of plant-based alternatives to dairy-based baby nutrition, is pleased to announce that it will be participating at this year’s NASPGHAN (North American Society for Pediatric Gastroenterology, Hepatology and Nutrition), November 1 st to 7 th .  Else’s virtual booth will enable live conversations with small groups, and one-on-one educational sessions, among the nearly 2,600 anticipated attendees. The forum will place Else Nutrition alongside some of the leading blue-chip nutrition companies, including Pfizer, Abbott Laboratories, Nestle and Danone.

“We are working diligently to build awareness of our products with America’s top pediatricians and medical experts” said Mrs. Hamutal Yitzhak , CEO and Co-Founder of Else. “We want them to form their own unbiased opinion of ELSE’s health benefits for babies and we are excited to introduce and promote our plant-based product to this professional crowd at NASPGHAN .  Educating the medical community is a major pillar of our marketing strategy,” she added.

This year’s annual summit is virtual due to COVID-19.

Else Nutrition’s Plant-Based Complete Nutrition for Toddlers & Babies (12+ mo.) is now available for sale on Else’s e-store at elsenutrition.com , and on Amazon.com.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean, plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition organizations. Many of Else advisory board  members held executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in prominent roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents.  Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate.  Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements.  Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Empower Clinics $CBDT.ca Growth Strategy Accelerates With Recent Major Initiatives. Updates Status And Outlook Into 2021 $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 7:23 AM on Monday, November 2nd, 2020

2020 Revenue Growth The Company has experienced significant revenue growth over the past year as evidenced by the following results:

  • 2019 + 86% To $2.03M
  • Q4 + 217% To $625,000
  • Q1 + 416% To $790,000
  • Q2 + 56% To $923,000

This performance has translated into the following year-to-date in 2020:

  • Revenue $1.7M vs $745K = 130% Growth
  • Patient Visits 12,400 vs 5,500 = 125% Growth

VANCOUVER BC / November 2, 2020 / EMPOWER CLINICS INC. Empower Clinics (CBDT:CSE)(EPWCF:OTC)(8EC:FRA) (the “Company” or “Empower“), an integrated healthcare company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and medical diagnostics laboratory, is pleased to provide shareholders with a status report on many initiatives announced over the past several weeks for the purposes of providing greater visibility into the Company’s outlook into 2021.

Steven McAuley, CEO of Empower Clinics stated “2020 is the year that established Empower Clinics as a formidable Health & Wellness Company with a solid foundation and great growth prospects. Given the speed at which we have been moving since I took over the leadership reigns in 2019, it is prudent to take a moment to provide our shareholders with both a current snapshot, as well as, our expectations for continued growth into 2021.”

HIGHLIGHTS & UPDATES

  • 2020 Revenue Growth The Company has experienced significant revenue growth over the past year as evidenced by the following results:
    • 2019 + 86% To $2.03M
    • Q4 + 217% To $625,000
    • Q1 + 416% To $790,000
    • Q2 + 56% To $923,000

This performance has translated into the following year-to-date in 2020:

  • Revenue $1.7M vs $745K = 130% Growth
  • Patient Visits 12,400 vs 5,500 = 125% Growth

Going forward, given the Company’s diversification into telemedicine, COVID-19 testing, medical laboratory testing for enterprise customers, and the proposed clinic expansion into Canada, all of which serves to diversify Empower well beyond our Southwestern U.S. clinic operations, going forward “patient visits” will be just one of many of the Company’s overall KPI’s (Key Performance Indicators).

  • Kai Medical Laboratory COVID-19 Testing Growth Includes Film & Television Industry Empower completed the closing of the Kai Medical Laboratory acquisition with the signing of the Member Purchase Interest Agreement October 5, 2020 and then subsequently completed the filing of all required regulatory documents with the State of Texas and other regulatory bodies.

The Company is now working through integration and implementing aggressive growth strategies including servicing new COVID-19 testing contracts for the film & television industry and supporting the Sun Valley Health COVID-19 RT-PCR and rapid antibody testing programs in the state of Arizona.

  • Sun Valley Health COVID-19 Regional Testing Growth Sun Valley Health with the support of Kai Medical Laboratory testing and medical billing capabilities, is expanding its RT-PCR testing with the commencement of drive-up testing for consumers in Mesa, Arizona and within clinic locations. The program allows the Company to provide free COVID-19 testing for consumers with Medicare and Medicaid insurance coverage in Arizona and for consumers who do not have active health insurance coverage in the state.
  • $1,100,000 Proposed Private Placement The previously announced proposed private placement with Mackie Research Capital Corporation as sole agent and sole bookrunner (the “Agent”) on October 21, 2020 remains on track for closing as planned on or about the week of November 2, 2020.
  • Canadian Clinic Acquisition The recently announced non-binding term sheet for the acquisition of Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc. dba Atkinson, and Momentum Health Inc. collectively (“Momentum Health”) is progressing as planned through the final due diligence phase with an anticipated closing in November 2020.
  • Q3 2020 Financial Statements The Company anticipates filing its third quarter 2020 financial statements and MD&A well in advance of the November 30, 2020 filing deadline. Financial and accounting controls supported by CFO Kyle Appleby enable the Company to maintain high compliance standards.

McAuley went on to say “Our company is rapidly evolving into providing an integrated healthcare experience that spans from testing to treatment by combining cutting edge technologies including telemedicine and state of the art lab testing. Add to this the fact that we are now serving enterprise level clients as promised and partnering on initiatives such as our recently announced travel bubble, it’s safe to say we are on the path to becoming a formidable small cap health & wellness company in 2021. I want to thank our loyal shareholders for trusting my leadership transition, welcome all of our newest shareholders and we look forward to delivering continued accelerated growth in 2021 and well beyond.”

ABOUT EMPOWER:

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with an expanded suite of physician-based services. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability and will lead our diagnostic and scientific advancement.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley

Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the anticipated date of closing of the Momentum Health acquisition and the occurrence thereof; the expected number of clinics and patients following the proposed closing; the future potential success of Kai Medical Laboratory; the future success of the Sun Valley’s franchise model; the completion of the private placement, date of closing or the occurrence of a closing; the impact if any of COVID-19 testing by Sun Valley Health and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Momentum Health acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Else Nutrition $BABY.ca $BABYF Plant-Based Infant Foods Launch in Over 380 US Retail Locations $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 4:09 PM on Friday, October 30th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Else Nutrition Holdings which develops plant-based alternatives to dairy milk-based baby foods, announces the early availability of its innovative products in US retail stores. The company expects to begin first retail sales through KeHE distributors in the western and southern regions of the United States as early as the end of November 2020.

Else began trading on the Toronto exchange last June and saw huge stock market interest upon its launch, being touted as hot stock to watch, in its plans to disrupt dairy nutrition for infants. Else says thats its products are the first viable choice other than dairy and soy in in this category for over 120 years.

Up to four regional customers and one national key account, for a total of 380 shops, will be served before the start of the Christmas season, following the recent successful launch of its plant-based baby food products through its online store and via Amazon. Else is now working diligently through a network of food brokers and KeHE sales partners to acquire strategic customers in the stationary trade in various key regions of the USA.

“The lively interest in our product makes us very optimistic. Parents and families have long been waiting for a plant-based alternative to milk-based baby food. Soon, parents across the United States will be able to buy our product in a shop near them and also order it through online retailing,” said Hamutal Yitzhak, CEO and founding member of Else.

Source: https://vegconomist.com/companies-and-portraits/else-nutrition-plant-based-infant-nutrition-launches-in-over-380-us-retail-locations/

Could #Cannabis Eliminate The High-Cost And High-Stakes Of Current #Psoriasis Medicines? SPONSOR: Innocan Pharma $INNO.ca $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 6:04 PM on Thursday, October 29th, 2020

SPONSOR: Innocan Pharma Corporation (INNO:CSE) (IP4:FSE) Innocan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products. In addition, the company filed an international patent application for a novel cannabis-based psoriasis treatment. This patent application makes claim of a topical pharmaceutical composition used to treat the symptoms of itching and inflammation associated with psoriasis.

  • “The global psoriasis drugs market is forecast to reach USD 39.00 Billion by 2027.
Innocan-Blog

Could Cannabis Eliminate The High-Cost And High-Stakes Of Current Psoriasis Medicines?

  • Often triggered by stress, new studies are showing that psoriasis can be better managed by diet, oral health, and even cannabidiol.
  • The National Psoriasis Foundation shared information on a study from the Journal of Dermatological Science showcasing that, “CBD may offer therapeutic value for psoriasis by slowing the overgrowth of certain skin cells.” 
  • A 2016 study published in the journal Current Clinical Pharmacology found similar results, citing that cannabinoids may be a positive addition to treatment for psoriasis.
  • Even better, a 2018 study did a sweeping review of prior research on cannabis’ role within dermatology and found, “cannabinoids have shown some initial promise as a therapy for a variety of skin diseases.” Their only concern was a lack of research in clinical trials, due to the Schedule 1 classification of the drug.  

By: Kate-Madonna Hindes

The National Psoriasis Foundation states that upwards of 8 million people have the auto-immune skin disorder. Often accompanied by arthritis, psoriasis not only causes scaling of the skin, but complications to fingernails as well. 

Affecting everyone from children to adults, psoriasis can lead to anxiety and depression, as individuals with the skin disorder are often afraid of being ridiculed. Usually treated with Humira and Enbrel, psoriasis comes with a shocking price tag and complications that are often difficult to ignore. 

A 2014 study published in the journal Drugs in Context found that Humira had a price tag upwards of $39,000, while Enbrel’s annual cost was around $46,000. Stelara, the most expensive drug, was found to cost over $53,000. As TNF blockers, while medications like Humira help against psoriasis, they can lower the body’s ability to fight infections and cause serious side effects.

Even more interesting, a September 2019 study in London found that, “A number of medications commonly prescribed by rheumatologists may interact with cannabidiol oil” (CBD oil). The most affected medicines appear to be corticosteroids (including hydrocortisone and prednisolone) since CBD, “is a potent inhibitor of CYP3A.” Put plainly, CBD may block the effects of the other medicine.

Image Credit: Aleksandr_Kravtsov | Getty Images via The Fresh Toast

Can CBD alone help psoriasis? 

Often triggered by stress, new studies are showing that psoriasis can be better managed by diet, oral health, and even cannabidiol. The National Psoriasis Foundation shared information on a study from the Journal of Dermatological Science showcasing that, “CBD may offer therapeutic value for psoriasis by slowing the overgrowth of certain skin cells.” 

A 2016 study published in the journal Current Clinical Pharmacology found similar results, citing that cannabinoids may be a positive addition to treatment for psoriasis. Even better, a 2018 study did a sweeping review of prior research on cannabis’ role within dermatology and found, “cannabinoids have shown some initial promise as a therapy for a variety of skin diseases.” Their only concern was a lack of research in clinical trials, due to the Schedule 1 classification of the drug.  

While CBD and cannabis offer pain relief and psoriasis is often accompanied by rheumatoid arthritis, each individual must discuss the addition of any new medicine (including CBD and cannabis) with their care team. With new clinical trials for cannabinoids and psoriasis recruiting even now, promising cures may be on the horizon.

Source: https://www.greenentrepreneur.com/article/358275

Else Nutrition $BABY.ca $BABYF Announces Successful Completion of Second Full-Scale Manufacturing Run and Commencement of Third Full-Scale Run in Early November $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 7:39 AM on Thursday, October 29th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Else has successfully completed a second commercial manufacturing run, 300% larger than the initial production run, and will commence a third manufacturing run in early November
  • This planned production run is expected to be 200% larger than the second run, and 600% larger than the inaugural one
  • Successful scale-up of production while maintaining a consistent and high-quality product is a major inflection point in the Company’s go-to market strategy
  • Else will generate additional inventory to service the Company’s expansion in the U.S. market as it rapidly expands into retail distribution, and scales its online sales

VANCOUVER, BC , Oct. 29, 2020  – ELSE NUTRITION HOLDINGS INC. (TSX-V: BABY) (OTCQX: BABYF) (FSE: 0YL) (” Else ” or the ” Company “), a commercial stage developer of plant-based alternatives to dairy-based baby nutrition, is pleased to provide an update on its North American product launch of its plant-based Toddler Nutrition product.

Else has successfully completed a second commercial manufacturing run, 300% larger than the initial production run, and will commence a third manufacturing run in early November. This planned production run is expected to be 200% larger than the second run, and 600% larger than the inaugural one. Successful scale-up of production while maintaining a consistent and high-quality product is a major inflection point in the Company’s go-to market strategy. As a result, Else will generate additional inventory to service the Company’s expansion in the U.S. market as it rapidly expands into retail distribution, and scales its online sales.

“We are encouraged by the early response to our long awaited product launch, and equally pleased to have to ramp up our inventory as we continue to see strong demand for our novel, clean-label, plant-based Toddler Nutrition product,” said Mrs. Hamutal Yitzhak , CEO and Co-Founder of Else.  “We are grateful for the very positive daily feedback from parents across North America , and look forward to bringing the product to store shelves soon.  Additionally, a consistent, high quality and scalable manufacturing process is a critical pillar of our business – we are pleased to have successfully completed two commercial scale runs and look forward to exponentially scaling the next one.

Else has completed the setup and order automation processes by signing up with a third-party logistics company. This provider has warehouses across the U.S. and Canada which will support Else’s E-commerce sales. Online order shipments have already commenced.

Else Nutrition’s Plant-Based Complete Nutrition for Toddlers & Babies (12+ mo.) is now available for sale on Else’s e-store at elsenutrition.com , and on Amazon.com. The Company also recently added subscription plans on its e-store.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board  members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies,  and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  

Caution Regarding Forward-Looking Statements  

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents.  Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate.  Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements.  Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

ImagineAR $IP.ca $IPNFF CEO Alen Paul Silverrstieen to Speak at the Global XR Bootcamp 2020 $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 7:29 AM on Thursday, October 29th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg
  • Alen Paul Silverrstieen, CEO of ImagineAR, will be speaking at the Global XR Bootcamp 2020
  • The Online Global XR Bootcamp 2020 will be the biggest online Virtual, Augmented and Mixed Reality event in the world and will be hosted November 13 th -14 th , 2020
  • The event will consist of a 24-hour live stream of high-quality sessions by global speakers planned around the world through all the time zones

VANCOUVER, BC and ERIE, Pa. , Oct. 29, 2020 – ImagineAR (CSE: IP) (OTCQB: IPNFF) an Augmented Reality Company that enables sports teams, brands and businesses to instantly create their own mobile phone AR campaigns, is pleased to announce that Alen Paul Silverrstieen, CEO of ImagineAR, will be speaking at the Global XR Bootcamp 2020.  The Online Global XR Bootcamp 2020 will be the biggest online Virtual, Augmented and Mixed Reality event in the world and will be hosted November 13 th -14 th , 2020. The event will consist of a 24-hour live stream of high-quality sessions by global speakers planned around the world through all the time zones.

Mr. Silverrstieen will be specifically addressing the utilization of mobile augmented reality for sports fan engagement and activation.

Alen Paul stated; “ImagineAR is expanding globally and this online event will provide the opportunity to introduce our augmented reality platform and mobile app SDK plugin to a new audience.  We have recently started marketing programs in the UK and Middle East.  Interest in utilizing AR for fan engagement has been growing in today’s new Covid-19 environment and we are excited to be launching the Valencia FC program this year.”

This press release is available on the Company’s AGORACOM Discussion Forum , a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Global XR BootCamp

The Online Global XR Bootcamp 2020 will be the biggest online Virtual, Augmented and Mixed Reality event in the world. The event will consist of a 24-hour live stream of high quality sessions by global speakers planned around the world through all the time zones.  Organizers have the ability to organize an online meetup in virtual reality as a community gathering. Watch content about virtual reality, augmented reality, mixed reality, WebXR and related technologies like machine learning and AI brought to you by local heroes, or just stop by to meet with others from the local community. https://www.globalxrbootcamp.com/

About ImagineAR

ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.

All trademarks of the property of respective owners.

ON BEHALF OF THE BOARD

Alen Paul Silverrstieen
President & CEO

(818) 850-2490

https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if ImagineAR IInc. (cse: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward-looking information is based on certain key expectations and assumptions made by ImagineAR management. Although ImagineAR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because ImagineAR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

#AR isn’t just ‘exciting’, it’s practical – SPONSOR: Imagine AR $IP.ca $IPNFF $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 1:47 PM on Wednesday, October 28th, 2020

SPONSOR: Imagine AR Inc. (IP:CSE) (IPNFF:OTCQB) is an Augmented Reality platform that allows businesses to easily launch AR campaigns. Clients Include: NBA Sacramento Kings, Mall of America, AT&T Shape and The Basketball Hall of Fame. ImagineAR and NFL Alumni Academy recently signed a 5 year partnership agreement. In addition, the company signed a two-year agreement with Valencia C.F. of La Liga to provide interactive Augmented Reality experiences for almost 7 million fans around the world. Learn More.

http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

AR isn’t just ‘exciting’, it’s practical

  • Augmented reality might seem like a daunting new frontier for the average business, but adopting this new technology is a lot easier than it seems
  • With an anticipated 3.8 billion smartphone users in 2021, more people are using mobile tech to experience the world, from enhanced museum tours to Animoji
  • If you haven’t already considered it, AR can be a smart, practical form of smart marketing and branding.

by Alexis Ong

Augmented reality might seem like a daunting new frontier for the average business, but adopting this new technology is a lot easier than it seems. With an anticipated 3.8 billion smartphone users in 2021, more people are using mobile tech to experience the world, from enhanced museum tours to Animoji. If you haven’t already considered it, AR can be a smart, practical form of smart marketing and branding.

First, it’s important to distinguish between augmented reality and virtual reality. Virtual reality is an almost wholly-digital experience that requires special hardware to immerse yourself in a new environment. Augmented reality is a combination of the digital and physical worlds, where the former is often “layered” over the latter. If you’ve used custom Snapchat filters or played Pokemon Go, you’ve already tried AR without even realizing it. 

But the great thing about AR is that it doesn’t require buying new hardware. Virtual reality, while still an exciting new realm, isn’t as widely accessible as AR. For starters, you need pricey new gadgets to play around in VR, but anyone with a smartphone and an internet connection can tap into a well-crafted AR experience. 

“The biggest benefit of AR is the simplicity with which you can build on top of the existing world that a user is already familiar with to teach them new things or show them new information that was previously unavailable,” says Gal Oppenheimer, who manages Contentstack’s Solutions Architecture Team. AR has, for instance, become a huge part of our daily reality, with Zoom virtual backgrounds helping people continue to meet and work collaboratively regardless of their environment. 

Speaking to Oppenheimer and Contentstack’s marketing director Varia Makagonova reveals that augmented reality is a particularly effective, forward-thinking strategy for companies in retail, museums/education, and home improvement; AR works best to convey important, relevant information to customers in a quick, intuitive way. Best of all, it’s surprisingly straightforward to implement, especially if you’re working with an experienced content management team. 

Great AR needs great content 

As a headless CMS, Contentstack leads the way in helping businesses create innovative content experiences. In 2020, blogs and websites are no longer the main avenues of brand communication – modern customer experiences can include everything from chatbots and apps to new types of streaming media. Contentstack helps you adapt to new technology quickly and seamlessly, no matter the platform. 

“When people look at AR, they only see the end experience,” says Oppenheimer. “And what people don’t realize is really there are two pieces to an AR experience. There’s the experience the consumer sees… and that is really just a 3D model, a color map, and a rendering library.” Then there’s the content, which can require just as much attention, depending on the scope of a company’s product lineup. This is where Contentstack comes into play. 

A great content platform needs to be streamlined and easy to use, especially if you’re going to be working with new channels and touchpoints like Augmented Reality applications. With the right tools, it’s easy to build a well-organized, flexible content library that can be used to power all kinds of content-rich experiences.   

And when it comes to retail, that often means making sure you can easily plug in personalization and e-commerce technologies into these experiences. As Oppenheimer points out, “it doesn’t matter if you have the biggest library of content available for your AR application to use. If the customer doesn’t see the one product that they are looking for to try on or learn more about, the app has not done its job for them.” 

Building and tending to a useful content experience doesn’t have to be painful, though. “We have customers that have well over 2 million products in their Contentstack,” Oppenheimer says. “And when they do a release, sometimes that’s 200 products going live the same day… being able to facilitate that process easily, and then making sure that content appears in the mobile application that has all the rich AR content at the end, that’s where we come in.”

Read More: https://thenextweb.com/augmented-reality/2020/10/28/ar-isnt-just-exciting-its-practical-heres-how-to-use-it-for-your-business/

ELSE Nutrition $BABY.ca $BABYF Toddler Products to Launch in Over 380 U.S. Retail Locations in November 2020 $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 7:22 AM on Wednesday, October 28th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • ELSE rapidly expands distribution to provide nationwide product availability in retail, Amazon.com and Else’s e-store
  • Company expects to begin its initial store distribution via KeHE Distributors in western and southern regions of the United States as early as late November 2020
  • To include up four regional accounts and one national key account, totaling 380 stores in advance of the Christmas season.
  • “We are very encouraged with the aggressive interest we have received for our product. Parents and families have waited a long time for a plant-based alternative to dairy-based baby nutrition….” said Mrs. Hamutal Yitzhak , CEO and Co-Founder of Else.

VANCOUVER, BC , Oct. 28, 2020 – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (” Else ” or the ” Company “), a commercial stage developer of plant-based alternatives to dairy-based baby nutrition, is pleased to  provide an update on upcoming availability of the Company’s products in U.S. retail stores.

The Company expects to begin its initial store distribution via KeHE Distributors in western and southern regions of the United States as early as late November 2020 , and is to include up four regional accounts and one national key account, totaling 380 stores in advance of the Christmas season.

U.S. Retail Distribution and Rollout

Following the recent successful e-store and Amazon launch for its plant-based toddler nutrition line, Else has been working diligently through its network of retail brokers and KeHE Distributors on strategic ‘Brick & Mortar’ account listings across various critical US regions.

“We are very encouraged with the aggressive interest we have received for our product. Parents and families have waited a long time for a plant-based alternative to dairy-based baby nutrition.  Soon parents across the United States will be able to find our product at stores near them in addition to being able to order online,” said Mrs. Hamutal Yitzhak , CEO and Co-Founder of Else.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board  members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies,  and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents.  Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate.  Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements.  Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Innocan Pharma’s $INNO.ca Relief & Go #CBD Spray Successfully Passes Safety Assessments and is Approved for Marketing in the European Union $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 5:12 PM on Tuesday, October 27th, 2020
Innocan-Blog
  • R&G Relief & Go™ CBD Spray product has successfully passed the detailed safety assessment requirements under Regulation No 1223/2009 of The European Parliament and of the Council on Cosmetic Products and has received a Cosmetic Product Safety Report (“CPSR”) for product marketing in the European Union
  • “We are thrilled to receive another validation of our feasibility and to pass the EU regulation requirements for the marketing of our Relief & Go CPD Spray product”, says Iris Bincovich, Co-founder and CEO of Innocan, “This is a major accomplishment for our team and an exciting milestone of our future”.

Herzliya, Israel and Calgary, Alberta–(October 27, 2020) –  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that its R&G Relief & Go™ CBD Spray product has successfully passed the detailed safety assessment requirements under Regulation No 1223/2009 of The European Parliament and of the Council on Cosmetic Products and has received a Cosmetic Product Safety Report (“CPSR”) for product marketing in the European Union.



Relief & Go

To view an enhanced version of this image, please visit:
https://orders.newsfilecorp.com/files/6922/66954_657f8b1b940c6910_002full.jpg

Innocan Israel, a wholly owned subsidiary of the Company, with its patent-pending unique formulation “Relief & Go CBD Spray” combines the known benefits of active ingredients such as Menthol and Camphor with CBD and Magnesium (more than 40% in the formula) to help the body relax and recover for sport-performing professionals. 

Innocan Israel’s CTO, Mr. Nir Avram has over 30 years of experience as a senior consultant in the area of pharmaceuticals and cosmetics. Nir consults in diverse areas of expertise including pharmaceutical and cosmetic innovations, generic formulations, and synthesis of novel materials, in connection with start-ups and established companies.

Nir is Vice President of Research & Development at Emilia Cosmetics Israel and Emilia Resources in the US. Prior to this he was VP of R&D at Careline, a leading cosmetics and toiletries manufacturer, and a member of the pharmaceutical innovation team at Perrigo.

“We are thrilled to receive another validation of our feasibility and to pass the EU regulation requirements for the marketing of our Relief & Go CPD Spray product”, says Iris Bincovich, Co-founder and CEO of Innocan, “This is a major accomplishment for our team and an exciting milestone of our future”.

About Innocan

Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable